Tiny fat bubbles carrying gene therapy have successfully repaired DNA in the lungs and liver of animals with alpha-1 ...

Excessive alcohol consumption causes alcoholic liver disease, and about 20% of these cases progress to alcohol-associated ...

Aerobic exercise and a high capacity for exercise may protect against metabolic dysfunction-associated steatotic liver ...

Steatotic liver disease often progresses asymptomatically, with the risk of advancing to cirrhosis and liver cancer. Early ...

Fatty liver disease is on the rise in modern times due to a range of lifestyle factors like a sedentary routine, a diet rich in processed food, alcohol consumption, and certain health conditions like ...

Trucchio sees 48-week data as key for Phase 3 progress, while William Blair questions drug's impact on fibrosis and weight loss at 24 weeks.

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver scarring in patients with fatty liver disease in a mid-stage trial.

By Denny Jacob Altimmune shares rose 13% in premarket trading following an announcement it would present topline 24-week data from its Phase 2b trial evaluating pemvidutide as a treatment for ...

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 liver disease study.

(Reuters) - Altimmune said on Thursday its experimental obesity drug met the main goal of a mid-stage trial studying it as a potential treatment for a fatty liver disease. The drug, pemvidutide, ...